The dynamic character of GPCRs (G-protein-coupled receptors) is essential to their function. However, the details of how ligands and signalling proteins stabilize a receptor conformation to trigger the activation of a given signalling pathway remain largely unexplored. Multiple data, including recent results obtained with the purified ghrelin receptor, suggest a model where ligand efficacy and functional selectivity are directly related to different receptor conformations. Importantly, distinct effector proteins (G-proteins and arrestins) as well as ligands are likely to affect the conformational landscape of GPCRs in different manners, as we show with the isolated ghrelin receptor. Such modulation of the GPCR conformational landscape by pharmacologically distinct ligands and effector proteins has major implications for the design of new drugs that activate specific signalling pathways.
Introduction
GPCRs (G-protein-coupled receptors) are major players in all cellular communication processes. As such, they actually represent major targets for drug development with applications in multiple clinical spheres [1] . Important progress has been made over the last years in understanding the molecular basis of GPCR-mediated signalling. In particular, spectacular developments in GPCR stabilization and crystallization have resulted in many different structures of active and inactive receptors [2] . These crystal structures provide an important framework to understand how agonists bind and how GPCRs subsequently get activated. However, they still represent unique states, whereas the dynamic character of receptors is essential for their physiological functions. Indeed, much data points to a model where GPCRs are highly dynamic proteins capable of adopting a large number of conformational states, which signal with different efficacies to various pathways [3] .
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of the methodology, these approaches actually benefit from the development of specific membrane mimicking media that help stabilize isolated receptors in solution. Among these media, two particularly promising systems have been recently developed: amphipols and nanodiscs. The pros and cons of these two membrane mimicking media have been recently reviewed [4] .
Conformational multiplicity in response to ligand binding
Much data point to a model where GPCRs are highly dynamic membrane proteins that can adopt a large number of conformational states. These conformational states, stabilized by distinct ligands, would interact with various efficacies with the different signalling proteins, thus providing a molecular basis to the observed differences in efficacy towards the multiple pathways associated with a single receptor [3] . The possible relationship between ligand-directed selectivity and receptor conformational multiplicity has been proposed from studies with receptors expressed in mammalian cell systems. In particular, RET (resonance energy transfer) technologies [e.g. FRET (fluorescence RET) and BRET (bioluminescence RET)] have been extensively used to assess whether biased signalling is related to distinct agonistinduced conformational changes. For instance, it has been shown that functionally different ligands trigger different conformational changes within the α 2A -AR (adrenergic receptor) [5, 6] , the δ-opioid receptor [7] or the β 2 AR [8] . More recently, using original BRET-based G-protein activation sensors, evidence has been provided suggesting that different ligands may stabilize distinct conformations of the AT 1A (angiotensin II type 1A) receptor, which would be associated with distinct signalling pathways [9] .
The most detailed molecular description of the conformational repertoire a GPCR can adopt in response to ligand binding has nevertheless been obtained with purified receptors isolated in membrane mimetic environments such as detergent micelles, bicelles or lipid nanodiscs. In particular, the β 2 AR has been extensively used to provide an experimental demonstration that ligands with distinct pharmacological properties shift the conformation of the receptor from one state to another. A series of experiments with fluorescently labelled β 2 AR provided the first direct demonstration that the conformation induced by a full agonist could be distinguished from that induced by partial agonists [10] . More recently, a quantitative mass spectrometry strategy was used to demonstrate that there is significant variability in the conformation of the receptor depending on the ligand [11] . In the same way, [ 19 F]-NMR has been used to show that different ligands trigger selective effects on the structural dynamics of the β 2 AR [12] . Besides the β 2 AR, other isolated GPCRs have been used to provide a detailed description of the conformational diversity of GPCRs. Spectroscopic methods such as CD and intrinsic fluorescence were applied to the serotonin (5-hydroxytryptamine; 5-HT) receptor 5-HT 4(a) stabilized in bicelles and indicated that ligands with different efficacies (full, partial and inverse agonists) stabilize different conformations [13] . LRET (lanthanide RET) studies with the purified vasopressin V2 receptor also demonstrated that a biased G-protein agonist-stabilized conformation is different from that triggered by an arrestinbiased ligand [14] .
More recently, we used a peptide-activated class A GPCR, the ghrelin receptor GHS-R1a (growth hormone secretagogue receptor 1a), to analyse how ligands impact on the conformation of this receptor. For this, the monomeric receptor was reconstituted into lipid disc particles and then labelled with a fluorescent conformational reporter, bimane [15] . As shown in Figure 1 , binding of all compounds besides the neutral antagonist is accompanied by a significant change in bimane emission, indicating that the receptor changes in conformation in response to the binding of these ligands. Of importance, these changes are different whether the ligand is a full agonist, a G q -biased agonist, a neutral antagonist or an inverse agonist. These results, along with the isolated ghrelin receptor, are consistent with those reported above for β 2 AR, serotonin or vasopressin receptors, and directly establish that pharmacologically distinct ligands stabilize different specific receptor conformations; these different conformational states are likely to be linked to the relative efficacy of the ligands in activating distinct signalling pathways. Some differences in this conformational diversity are nevertheless observed depending on the receptor considered. For instance, we observed no difference for structurally distinct but pharmacologically related ligands [15] , indicating that the compounds we used follow similar trends of receptor conformational signature dependent on their pharmacological properties rather than on their structure. This is different from what has been reported with the β 2 AR where distinct conformational patterns have been observed for pharmacologically similar ligands [11] . This may be related either to the method we used with the ghrelin receptor, whereby some changes in conformation remain invisible if they do not affect the environment of the fluorescent probe, or to the fact that some aspects of this conformational multiplicity model may be receptor dependent. Nevertheless, our data, associated with those previously reported for instance with the purified β 2 AR, the serotonin or the vasopressin receptors, strongly favours a model where the conformational landscape of the receptor observed in response to the binding of ligands is directly related to the pharmacological profile of the compounds.
Conformational multiplicity in response to coupling to signalling protein
Although, as stated above, ligand-induced conformational changes in GPCRs are well documented, there is less evidence to describe the changes in GPCR conformation induced by associated signalling proteins. Cysteine accessibility methods have been used to assess G-proteins that affect the accessibility of some residues located in the TM (transmembrane) 6, TM7 and extracellular loop 2 of the κ-opioid receptor, indicating that coupling to the G-protein indeed affects receptor structure [16] . Based on spectroscopic studies with rhodopsin and the β 2 AR, it had been proposed that binding of the G-protein to the receptor active state(s) further changes the energy stabilizing of the ternary complex, which then becomes the predominant conformation [17] . This has been confirmed through the ultimate elucidation of the structure of the β 2 AR bound to an agonist in the absence and in the presence of either G s or a G s -mimicking nanobody [18, 19] . Comparison of these crystal structures indicates that the binding energy from a G-protein is indeed required to stabilize the active conformation.
We also analysed the effects of coupling with signalling proteins (e.g., arrestin and G-protein) on the conformation of the ghrelin receptor again using bimane as a fluorescent probe [15] . Whenever a significant GHS-R1a-catalysed G q activation can be measured (in the absence of ligand and in the presence of a full or G q -biased agonist), coupling to G q is accompanied by a significant change in bimane emission compared with what is observed in the absence of the G-protein (Figure 1 ). An analysis of the bimane fluorescence lifetime decay in the presence G q gives a lifetime distribution closely related to that obtained in the absence of the G-protein, suggesting that coupling to G q does not stabilize an additional receptor conformation but rather further increases the stability of the active state [15] . This is consistent with the energy landscape model proposed by Deupi and Kobilka [17] . Based on this model, agonist binding to the receptor would increase the dynamics of the receptor. This would populate active conformations of lower energy. Binding of the G-protein would then in turn decrease the dynamic behaviour of the agonist-receptor complex, and by doing so would stabilize the active conformation in the ligand-receptor-G-protein complex; this active receptor conformation would then become the predominant one, as observed experimentally with the ghrelin receptor.
We have also analysed the effects of another major signalling protein, arrestin-2, on the ghrelin receptor conformational landscape [15] . As is the case with the Gprotein, adding arrestin in the presence of a compound that triggers arrestin recruitment also affects bimane emission intensity (Figure 1 ). However, in contrast with G-protein coupling, the change in bimane emission intensity is observed only in the presence of the agonist. This suggests that coupling of the ghrelin-activated receptor to arrestin is accompanied by the occurrence of a receptor conformation different from that observed in the presence of ghrelin alone or in the presence of ghrelin and G q . Arrestin and G-proteins would thus affect the conformational landscape of the ghrelin receptor in a different way. Whereas coupling to G-proteins would essentially populate the agonist-stabilized conformation, coupling of the agonist-activated receptor to arrestin-2 would populate a conformation different from that stabilized in the presence of G q . Such a difference in the conformational features of the receptor bound to G-proteins or arrestin is likely to be related to the subsequent effects on signalling.
Conclusion
Providing a clear description of the way different chemically structured compounds can modulate GHS-R1a-mediated signalling is essential for both academic and drug-design purposes. A wealth of data favours a model where selection of different signalling pathways is associated with the stabilization of a given receptor conformation in response to ligand binding. Our experimental results regarding the ghrelin receptor reinforce this model by suggesting that pharmacologically distinct ligands trigger different receptor conformation. Moreover, signalling proteins in addition to ligands can have an impact on the conformational landscape that the receptor can adopt. Such a modulation of GPCR conformational landscape by functionally different ligands and effectors is to be associated with the way efficacy in signalling is controlled.
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